Denali Therapeutics Inc (DNLI)

Etorro trading 970x250

About Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson’s disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson’s disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer’s disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. Address: 161 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Denali Therapeutics Inc News and around…

Latest news about Denali Therapeutics Inc (DNLI) common stock and company :

Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change
13 Oct, 2021 Yahoo! Finance

Invaio Sciences, Inc., a Flagship Pioneering company unlocking the potential of natural systems to accelerate the transition to sustainable agriculture to urgently address climate change, has entered into a $50 million loan and security agreement with K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm.

New Strong Sell Stocks for October 12th
12 Oct, 2021 Yahoo! Finance

ONEM, DNLI, FMC, GPL, and LGO have been added to the Zacks Rank #5 (Strong Sell) List on October 12, 2021.

Denali Therapeutics Insider Trades $500K In Company Stock
07 Oct, 2021 Yahoo! Finance

Alexander Schuth, COO And Secretary at Denali Therapeutics (NASDAQ:DNLI), made a large insider sell on October 4, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Schuth sold 10,000 shares of Denali Therapeutics at prices ranging from $50.24 to $51.04. The total transaction amounted to $505,605. Schuth still owns a total of 559,537 shares of Denali Therapeutics worth, $28,530,791. Denali Therapeutics shares are t

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
07 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Denali Highlights Encouraging Early Data, Update For Amyotrophic Lateral Sclerosis Program
07 Oct, 2021 FinancialContent

Denali Therapeutics Inc(NASDAQ: DNLI)announced datafrom the Phase 1 trial evaluating DNL343, eIF2B activator, in 95 ...

Denali Therapeutics Announces Positive Clinical Results and Regulatory Progress for Development Programs in Amyotrophic Lateral Sclerosis (ALS)
06 Oct, 2021 Yahoo! Finance

eIF2B activator DNL343 achieved safety and biomarker goals in a Phase 1 study in healthy volunteers; a Phase 1b study began in individuals with ALS in Q3 2021Fast Track designation granted by the U.S. Food and Drug Administration (FDA) to SAR443820/DNL788, a RIPK1 inhibitor, for the treatment of ALS; Sanofi to initiate Phase 2 study in individuals with ALS in Q1 2022Denali to host webinar for analysts and investors today, October 6, at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., Oct. 06,

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
03 Oct, 2021 FinancialContent

Biotech stocks came under pressure in the week endingOct. 1, dragged by broader market weakness and the selling ofvaccine ...

Denali Therapeutics Announces Upcoming Presentations on EIF2B Activator DNL343 and RIPK1 Inhibitor SAR443820/DNL788 at the 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting
29 Sep, 2021 FinancialContent
Denali Therapeutics Appoints Katie Peng as Chief Commercial Officer
27 Sep, 2021 FinancialContent

Proven commercial leader with broad global experience in building and running commercial organizations and successfully launching products for people with neurological and rare diseases

Oppenheimer Says There’s Room for Over 50% Gains in These 3 Stocks
26 Sep, 2021 Yahoo! Finance

There is an old Chinese curse that says “May he live in interesting times.” Like it or not, we live in interesting times. COVID is receding but not gone, and while markets have rebounded well from the crisis (the S&P 500 is up 19% so far this year), the general economy is showing some worrisome signs. Jobs creation slowed in August, and employers reported over 11 million unfilled positions – but unemployment, while ticking down, remains above 5%. More ominously, in an indication that supply chai

Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2021
21 Sep, 2021 FinancialContent

Upgrades According to Compass Point, the prior rating for TriplePoint Venture Growth BDC Corp (NYSE:TPVG) was changed from Neutral to ...

Analysts Expect FNY To Hit $86
20 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Mid Cap Growth AlphaDEX Fund ETF (FNY), we found that the implied analyst target price for the ETF based upon its underlying holdings is $85.75 per unit.

Denali Therapeutics Announces Initiation of Phase 1b Study of EIF2B Activator DNL343 in ALS
09 Sep, 2021 FinancialContent

— Investigational EIF2B activator approach has potential to be a first-in-class treatment for ALS —

Denali Therapeutics Inc. (DNLI) Up 5.7% Since Last Earnings Report: Can It Continue?
03 Sep, 2021 Yahoo! Finance

Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

President And CEO Of Denali Therapeutics Sold $1.00 Million In Stock
03 Sep, 2021 FinancialContent

Ryan Watts, Presidentand CEO at Denali Therapeutics (NASDAQ:DNLI), made a large insider sell on September 1, according to a new ...

Denali Therapeutics Announces Publication in Cell on New Approach to Treat FTD-GRN
26 Aug, 2021 FinancialContent

Preclinical studies show enhanced brain uptake of progranulin can be achieved using Denali’s Transport Vehicle to cross the blood-brain barrier

My 2019 Report Card: Up 319%
15 Aug, 2021 FinancialContent

I made 63 bullish calls involving 45 companies in 2019. Here are the winners, the stinkers, and everything in between.

8 Best Stocks to Buy According to Billionaire Nicholas J. Pritzker’s Tao Capital
09 Aug, 2021 Yahoo! Finance

In this article, we will be discussing 8 best stocks to buy according to billionaire Nicholas J. Pritzker based on his hedge fund’s Q1 portfolio. To skip our detailed analysis of Nicholas J. Pritzker’s hedge fund returns, investment philosophy, and history, you can click to skip ahead to 4 Best Stocks to Buy According to […]

Denali Therapeutics Inc. (NASDAQ:DNLI) Analysts Are Reducing Their Forecasts For This Year
06 Aug, 2021 Yahoo! Finance

Market forces rained on the parade of Denali Therapeutics Inc. ( NASDAQ:DNLI ) shareholders today, when the analysts...

Is Denali Therapeutics Inc.'s (NASDAQ:DNLI) Stock Price Struggling As A Result Of Its Mixed Financials?
05 Aug, 2021 Yahoo! Finance

It is hard to get excited after looking at Denali Therapeutics' (NASDAQ:DNLI) recent performance, when its stock has...

Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Lags Revenue Estimates
04 Aug, 2021 Yahoo! Finance

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -35.14% and -28.56%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Denali Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights
04 Aug, 2021 FinancialContent
Will Denali Therapeutics Inc. (DNLI) Report Negative Q2 Earnings? What You Should Know
30 Jul, 2021 Yahoo! Finance

Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Denali Therapeutics Moves Up In Market Cap Rank, Passing Unum Group
28 Jul, 2021 FinancialContent

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Denali Therapeutics Inc (DNLI) was identified as having a larger market cap than the smaller end of the S&P 500, for example Unum Group (UNM), according to The Online Investor. Click here to find out the top S&P 500 components ordered by average analyst rating » Market capitalization is an important data point for investors to keep an eye on, for various reasons..

74 Biggest Movers From Yesterday
27 Jul, 2021 FinancialContent

Gainers Bit Digital, Inc. (NASDAQ: BTBT) shares jumped 109.7% to close at $8.87 on Monday after the company announced it entered ...

Why Denali Therapeutics Stock Is Sinking Today
26 Jul, 2021 FinancialContent

The company reported interim results from a phase 1/2 study of its experimental Hunter syndrome drug.

48 Stocks Moving In Monday's Mid-Day Session
26 Jul, 2021 FinancialContent

Gainers Bit Digital, Inc. (NASDAQ: BTBT) gained 38% to $5.83 after the company announced it entered into a second strategic ...

Denali Therapeutics Stock Crashes; Why Investors Are Questioning Its Entire Pipeline
26 Jul, 2021 FinancialContent

Denali unveiled promising test results in Hunter syndrome, but DNLI stock tanked Monday on broader pipeline questions.

12 Health Care Stocks Moving In Monday's Pre-Market Session
26 Jul, 2021 FinancialContent

Gainers Dynatronics (NASDAQ:DYNT) shares moved upwards by 40.31% to $1.81 during Monday's pre-market session. The ...

Denali Therapeutics Inc (DNLI) is a NASDAQ Common Stock listed in , ,

970x250